- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00215774
Flecainide-Short Long Study (Flec-SL)
Targeted Pharmacological Reversal of Electrical Remodeling After Cardioversion.
Study Overview
Detailed Description
Details of the trial are described in a design paper published in the American Heart Journal (1).
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with approximately one million affected patients in Germany. Current estimates suggest that the life-time risk for AF is 30% for men and slightly less for women at the age of 40 years. Due to demographic changes in the German population, the incidence and prevalence of AF is expected to double within the next 30 years. AF almost doubles mortality and causes important morbidity, mainly due to thrombo-embolic complications and stroke. In addition, the arrhythmia in itself reduces the chronotropic adaptation of the heart to increased work load and reduces cardiac output, especially in patients with heart failure or other cardiac disease. Restoration of sinus rhythm would reduce this burden of disease.
Acute termination of AF is almost always successful by external electrical cardioversion, especially using recently optimized techniques [biphasic shock wave forms, anterior-posterior electrode position, sintered steel electrode paddles. Maintaining sinus rhythm, however, is a more difficult task. Antiarrhythmic, ion channel-blocking drugs are effective in preventing a part of recurrent episodes of AF. Their long-term use, however, is limited by pro-arrhythmic side effects which are especially apparent during long-term therapy. AF initiates major changes in atrial electrophysiology per se which have been summarized as "electrical remodeling". The main consequence of these changes is a shortening of the atrial refractory period and action potential duration. Electrical remodeling maintains AF and is related to recurrence of AF after successful cardioversion. Electrical remodeling is reversed when sinus rhythm is maintained over approximately 4 weeks after successful cardioversion. Interestingly, the vast majority of AF recurrences occur during these first few weeks after cardioversion.
Conceptually, the initial phase of "reversal" of electrical remodeling can be separated from the long-term treatment aimed at modifying the underlying substrate of AF. Classical sodium- or potassium channel blocking antiarrhythmic drugs prolong the atrial action potential even in the fibrillating atrium and may therefore support or even anticipate reversal of electrical remodeling. Such pharmacological reversal of electrical remodeling may only transiently be required, i.e. until electrical remodeling is in itself reversed by the natural restoration of normal atrial electrophysiology. Atrial action potential prolongation beyond normal values may indeed even be pro-arrhythmic. Therefore, it is tempting to treat the main electrophysiological end point of electrical remodeling, shortening of atrial action potential duration, by a limited short-term use of action potential-prolonging antiarrhythmic drugs.
Hypothesis: Targeted "pharmacological reversal" of atrial remodeling by short-term administration of action potential prolonging antiarrhythmic drugs (4 weeks therapy duration) is equally efficient and potentially safer to prevent recurrent AF after cardioversion when compared to current long-term antiarrhythmic drug therapy.
Trial design: This is a prospective, randomized, controlled, open label, parallel group multi-center investigator-initiated trial. The study medication is prescribed in an open fashion. We chose an open design in order to increase external validity ("relevance for clinical practice") of the results.
After successful cardioversion, patients will be randomized to one of three treatment groups:
Group A: No antiarrhythmic treatment
Group B: 4 weeks antiarrhythmic treatment with flecainide
Group C: Standard long term antiarrhythmic treatment (6 months) with flecainide
Group sizes were calculated to allow demonstration of non-inferiority of the two active treatment arms with a 10% boundary.
Flecainide was chosen for antiarrhythmic treatment in the Flec-SL trial because it is effective in the prevention of recurrent AF after cardioversion in the absence of major structural heart disease, has been safe as an outpatient treatment for recurrent AF, and prolongs the atrial action potential in patients with AF. In addition to its action potential-prolonging effect, flecainide induces post-repolarization refractoriness in the atria, an electrophysiological effect that may assist in the prevention of recurrent AF.
This is an investigator-initiated trial. Sponsor is the AFNET (www.kompetenznetz-vorhofflimmern.de).
Primary end point is the time to persistent AF as assessed by daily telemetric ECG recordings and confirmed by conventional Holter ECG recordings. Secondary end points include burden of AF, time to first symptomatic episode of AF, AF burden (number and duration of AF episodes), number of hospitalizations due to AF, time to termination of trial medication, number of serious adverse events including pro-arrhythmic events, and quality of life. Details of the secondary end points are indicated in the approved trial protocol.
All patients are systematically followed for 6 months by daily telemetric ECG recordings. All recordings are obtained using miniaturized ECG recorders which allow recording of a 60-second ECG and transtelephonic ECG transmission of the ECG via a toll-free number. All ECGs are received at the central analysis unit located at the Institute for Clinical Cardiovascular Research (IKKF) in Munich. Each telemetric ECG is analyzed within 24 hours of receipt at the analysis unit. The study physician is informed in case of any abnormal results within these 24 hours. Suspicion of persistent atrial fibrillation in the Tele-ECG prompts a local visit to record a Holte ECG. The Holter ECGs are centrally analyzed (blinded end point analysis). The systematic telemetric ECG monitoring allows for detection of all episodes of recurrent persistent AF.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented persistent atrial fibrillation
- Age of 18 years
- Documented oral anticoagulation (INR ≥ 2) for at least three weeks prior to inclusion, or exclusion of left atrial thrombi by trans-esophageal echocardiography
- Written informed consent of the patient
Exclusion Criteria:
- Current therapy with antiarrhythmic agents of class I and class III other than study medication flecainide. Such antiarrhythmic treatment must be stopped five half lives prior to enrollment. Five half lives correspond to 48 hours for almost all antiarrhythmic agents. For details regarding a specific agent, this information can be obtained through the internet at www.rote-liste.de or from the Fachinformation of the specific compound.
- Long-term therapy with amiodarone within the last 6 months prior to inclusion
- Symptomatic bradycardia or symptomatic sick sinus syndrome unless treated with a permanent pacemaker
- Symptomatic higher degree AV nodal block (grade II or III) unless treated with a permanent pacemaker
- Brugada syndrome
- Typical angina pectoris symptoms at rest or during exercise
- Known untreated coronary artery disease with high-degree coronary stenosis (> 80% reduction in luminal diameter)
- Myocardial infarction within the last 3 months
- Left ventricular ejection fraction of more than 40%
- Creatinine clearance < 50 ml/min*1.73 m2 as determined by the Cockroft-Gould formula. The digital data management system will calculate this value for you during the inclusion process. For completeness of documentation, the formula is given below:
- Men: Creatinine clearance (ml/min) = (140 - age(years)) * body weight (kg) / (72 * serum creatinine level (mg/dl))
- Women: Value for men * 0,85
- Manifest hepatic insufficiency
- Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH, T3, T4)
- Females who are pregnant or breast feeding
- Females of childbearing potential who are not using a scientifically accepted method of contraception
- Participation in a clinical trial within the last 30 days. Simultaneous participation in a registry (e.g. project AB1 of the AFNET) is permitted.
- Drug addiction or chronic alcohol abuse
- Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical trial
- Evidence of an uncooperative attitude
- Prolongation of the QRS complex by more than 25% during flecainide treatment (measured as the difference in QRS duration between the baseline ECG and the ECG at cardioversion (34))
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No antiarrhythmic treatment
Control group
|
|
Experimental: B-Flecainide treatment
4 weeks treatment with flecainide
|
Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
Other Names:
|
Experimental: C-Flecainide treatment
6 months flecainide treatment
|
Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
time to persistent atrial fibrillation as determined by daily telemetric ECG recordings and verified by Holter ECG recording
Time Frame: primary endpoint
|
primary endpoint
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
time to first symptomatic episode of AF
Time Frame: end of trial
|
end of trial
|
AF burden (number and duration of AF episodes)
Time Frame: end of trial
|
end of trial
|
number of hospitalizations due to AF
Time Frame: end of trial
|
end of trial
|
time to termination of trial medication
Time Frame: end of trial
|
end of trial
|
number of serious adverse events including pro-arrhythmic events
Time Frame: end of trial
|
end of trial
|
quality of life
Time Frame: end of trial
|
end of trial
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: P Kirchhof, Prof, AFNET, Kompetenznetz Vorhofflimmern
- Principal Investigator: G Breithardt, Prof, AFNET, Kompetenznetz Vorhofflimmern
Publications and helpful links
General Publications
- Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J. 2005 Nov;150(5):899. doi: 10.1016/j.ahj.2005.07.020.
- Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012 Jul 21;380(9838):238-46. doi: 10.1016/S0140-6736(12)60570-4. Epub 2012 Jun 18. Erratum In: Lancet. 2012 Oct 13;380(9850):1308.
- Apostolakis S, Haeusler KG, Oeff M, Treszl A, Andresen D, Borggrefe M, Lip GY, Meinertz T, Parade U, Samol A, Steinbeck G, Wegscheider K, Breithardt G, Kirchhof P. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial. Int J Cardiol. 2013 Oct 9;168(4):3977-81. doi: 10.1016/j.ijcard.2013.06.090. Epub 2013 Jul 18.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFNET-B11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Flecainide
-
MEDA Pharma GmbH & Co. KGCompletedAtrial FibrillationFrance
-
NYU Langone HealthCompletedBrugada Syndrome | Arrhythmogenic Right Ventricular CardiomyopathyUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
Assistance Publique - Hôpitaux de ParisFonds de Dotation ACTIONActive, not recruitingPatent Foramen Ovale | Cryptogenic Stroke | Atrial ArrhythmiaFrance
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Heart Arrest | Death, Sudden, Cardiac | Ventricular Arrhythmia
-
TheranexusCompleted
-
Wojciech ZarebaCompletedArrhythmogenic Right Ventricular CardiomyopathyUnited States
-
InCarda Therapeutics, Inc.CompletedParoxysmal Atrial Fibrillation (PAF)Netherlands, Belgium
-
University of Wisconsin, MadisonTerminatedBlood Pressure | Ventricular Premature ComplexesUnited States
-
Edgar JaeggiCanadian Institutes of Health Research (CIHR)Active, not recruitingFetal Atrial Flutter Without Hydrops | Fetal Supraventricular Tachycardia Without Hydrops | Fetal Supraventricular Tachycardia With HydropsUnited States, Canada, Germany, Australia, Netherlands, United Kingdom